Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) and its partners have at least 25 compounds in clinical development, excluding line extensions and drugs already marketed by the Japanese pharma in various territories. Twenty of the compounds were generated internally, while five were in-licensed. At least 17 of these are against a novel target — one to which no marketed drug binds. (A) Hits novel target; Source: Kyowa Hakko Kirin

Product Description Indication Status Partner
In-house
Tivopath tivozanib (ASP4130, AV-951, KRN951 Inhibitor of VEGF receptor 1 (FLT1; VEGFR-1), VEGF receptor 2 (KDR/Flk-1; VEGFR-2) and VEGF receptor 3 (FLT4; VEGFR-3) Cancer 7/28/13 PDUFA in U.S.; Ph I in Japan Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) has ex-Asian rights;  Aveo partnered with Astellas Pharma Inc. (Tokyo:4503) 
Istradefylline (KW-6002) (A) Adenosine A2A receptor (ADORA2A) antagonist Parkinson's disease (PD) Filed in U.S. and Japan